AFRICAN AMERICAN STUDY OF KIDNEY DISEASE AND HYPERTENSIO

描述(直接从应用程序中获取) 有证据表明，非洲的高血压发病率 美国人(AA)明显高于白人，而且 AA的肾脏更容易患高血压；而对于任何 在给定的血压升高水平下，再障患者的肾脏循环可能 遭受更大的伤害。因此，终末期肾脏的发生率 再生障碍性贫血的高血压患病率比白人高好几倍。 事实上，在洛杉矶，每天都有一名新的再生障碍性贫血患者开始透析治疗 高血压引起的肾功能衰竭。目前尚不清楚是否会更加严格 控制高血压(平均动脉压低于92毫米汞柱)优于平时 控制高血压(MAP 102-107毫米汞柱)保护肾功能 在戒酒协会。此外，其他数据表明，某些降压药 例如血管紧张素转换酶抑制剂(ACEI)或钙 通道阻滞剂(CCB)可能更好地延缓肾功能衰竭的进展 而不是其他药物。因此，一项检查疗效的对照研究 对这些药物的影响和两个水平的血压控制 关于高血压患者肾功能衰竭的进展，需要进行AA。 拟议的研究是多中心、前瞻性、双重化研究的一部分。 三种药物疗效的随机对照临床试验 方案(ACEI、CCB和B-受体阻滞剂)和两种不同水平的MAP 对照组(低于92毫米汞柱对102-107毫米汞柱)。因此，接下来将进行这项研究 三乘二析因设计。研究的结果将估计 三个治疗组固定时间内肾小球滤过率的变化 和两个水平的血压控制。 南加州大学(USC)马丁·路德·金-德鲁 医疗中心(MLK)和港湾综合医院-加州大学洛杉矶分校(HGH)是三家 提供肾脏疾病和高血压护理的主要机构 在洛杉矶生活的一百万戒酒协会中。这三个机构 在AASK的试点研究期间组成了一个财团，并已 他们在招聘工作中取得了成功。我们将继续这样做 联合进行全面研究，并将利用我们的专业知识， 经验和承诺，使我们的工作取得成功 这项多中心研究。

DESCRIPTION (taken directly from the application) Evidence exists suggesting that the incidence of hypertension in African Americans (AA) is markedly and significantly higher than in whites, and that the kidneys of AA are more susceptible to hypertension; and for any given level of blood pressure elevation, the renal circulation in AA may be subjected to a greater injury. Thus, the incidence of end stage renal disease due to hypertension in AA is several times higher than in whites. Indeed every day in Los Angeles, one new AA begins dialysis treatment for renal failure due to hypertension. It is not known whether stricter control of hypertension (MAP less than 92 mmHg) is superior to the usual control of hypertension (MAP 102-107mmHg) in protecting renal function in AA. Further, other data suggest that certain antihypertensive drugs such as angiotensin converting enzyme inhibitors (ACEI) or calcium channel blockers (CCB) may retard progression of renal failure better than other medications. Thus, a controlled study examining the efficacy of these drugs and the impact of two levels of blood pressure control on the progression of renal failure in hypertension AA is needed. The proposed research is a part of a multicenter, prospective, double masked randomized clinical trial examining the effect of three drug regimens (ACEI, CCB and B-blockers) and two different levels of MAP control (less than 92 versus 102-107 mmHg). Thus, the study will follow a three by two factorial design. The outcome of the study will estimate the changes in GFR in a fixed time period among the three treatment arms and the two levels of blood pressure control. The University of Southern California (USC), Martin Luther King-Drew Medical Center (MLK) and Harbor General Hospital-UCLA (HGH) are three major institutions which provide care for renal diseases and hypertension among the one million AA living in Los Angeles. These three institutions have teamed in a consortium during the pilot study of AASK and have been successful in their recruitment efforts. We will continue this consortium for the full scale study and will use our expertise, experience and commitment to bring to successful fruition our part in this multicenter Study.